VanEck Ethereum ETF Q2 2026: NAV decline, net assets down $25.8M — 10-Q Summary

VanEck Ethereum ETF (ETHV) reported Q2 2026 net assets from operations of -$25.8M, and -$70.6M for the first six months ended June 30, 2026, citing Ether price declines and net redemptions. NAV per share fell to $23.23 from $36.41 a year earlier. Assets under management fell 50.6% YTD to $77.8M.

Original reporting
Published Aug 13, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
VanEck Ethereum ETF Q2 2026: NAV decline, net assets down $25.8M — 10-Q Summary — source image
Decision brief

The 30-second read

$ETHVBearishMed
01

Why it matters

The disclosed NAV per share decline, net assets from operations deterioration, and net redemptions provide a concrete read-through on investor flows and valuation pressure for an ETH-linked ETF.

02

Market read

Traders can use the filing’s quantified NAV/AUM/share-count changes to gauge flow and valuation pressure in an ETH-linked ETF wrapper.

03

What to watch

Fee waivers by the sponsor may cushion cash outflows, so the NAV decline is not purely mechanical from ETH price; flow-driven share reduction also matters for near-term performance.

Relevance 6/10Novelty 6/10Timing: post-market, based on Aug. 13, 2026 10-Q filing

Background

The article summarizes VanEck Ethereum ETF’s SEC 10-Q, focusing on Q2 2026 operations, NAV, and AUM changes.

Company-level read

Ticker impact

$ETHVBearishMedium confidence
Context

VanEck Ethereum ETF 10-Q reports NAV per share fell to $23.23 at June 30, 2026 from $36.41 a year ago, driven by Ether price declines and redemptions.

Expected impact

Expect continued sensitivity to ETH price and redemption flow dynamics; ETF performance likely remains pressured while ETH weakens or outflows persist.

Evidence & confidence

The filing provides specific NAV/AUM/share-count changes and attributes them to ETH price decline plus higher redemptions than creations, which directly affects ETF valuation and investor demand.

Market effects

Highlights how spot-ETH exposure vehicles can see NAV compression and outflows when ETH sells off, reinforcing flow sensitivity in crypto ETF wrappers.

Primarily US-listed crypto-ETF sentiment, with limited direct regional spillover beyond investor positioning.

Reflects global ETH price weakness translating into ETF NAV and AUM declines, reinforcing cross-market crypto risk appetite.

Counterpoint

If ETH stabilizes, the ETF’s passively tracked structure could allow NAV to recover quickly, making the reported weakness potentially transient.

Key entities

  • VanEck Ethereum ETF

    Passively tracks Ether exposure; reported NAV and AUM declines in Q2 2026 tied to ETH price weakness and net redemptions.

  • Ether (ETH)

    Primary trust holding; ETH price fell materially over the period, driving ETF performance.

Related articles

$NVDAMed

Nvidia highlights open models amid leadership shakeup

Nvidia's interim CEO Colette Kress discussed the company's commitment to open models during an earnings call, projecting 75% revenue growth. She highlighted partnerships with Microsoft, Salesforce, and others, and announced $390 billion in infrastructure investments for Q3. Despite leadership uncertainty, Kress emphasized Nvidia's strong market position and multiyear roadmap.

$PFEMedAI 8/10

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Pfizer and Blackstone Life Sciences agreed to co-fund berobenatide, a GLP-1 drug for weight management, with Blackstone covering up to $1.5B in development costs. Pfizer retains control. J&J acquired Ollin Biosciences for $2.2B, Lilly acquired Calytrix Bio for up to $1.5B, and Sanofi partnered with Seawolf Therapeutics. Gilead licensed obeldesivir to generic manufacturers for Ebola prevention. The FDA approved Novartis' Cosentyx for polymyalgia rheumatica and Roche's Wilserdly for breast cancer.